NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 9 March 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Dr Hatim Abdulhussein Items 5.1.1 to 5.2
4. Mariana Bacelar Present for all items
5. Maria Brezitski Items 1.1 to 4.3.2
6. Professor Francis Drobniewski Items 5.1.1 to 5.2.2
7. Dr Bushra Hasnie Present for all items
8. Dr Veline L’Esperance Present for all items
9. Dr Warren Linley Items 5.1.1 to 5.2.2
10. Professor David McAllister Items 1.1 to 4.3.2
11. Stella O’Brien Items 1.1 to 4.1.3
12. Dr Rhiannon Owen Present for all items
13. Dr Alistair Patton Items 4.1.3 to 5.1.3
14. Anna Pracz Present for all items
15. Gabriel Rogers  Present for all items
16. Dr Toby Smith Items 1.1 to 5.2
17. Nigel Westwood Present for all items
18. Peter Wheatley-Price Present for all items
19. Dr Stuart Williams Present for all items
20. Tony Wootton Present for all items

NICE staff present

Richard Diaz, Associate Director Items 5.1 to 5.2.2

Ross Dent, Associate Director Items 1.1 to 4.3.2

Jeremy Powell, Project Manager Items 1.1 to 4.3.2

Daniel Davies, Project Manager Items 5.1 to 5.2.2

Eleanor Donegan, Health Technology Assessment Adviser Items 1.1 to 4.1.3

Yelan Guo, Health Technology Assessment Adviser Items 5.1 to 5.2.2

Summaya Mohammad, Health Technology Assessment Analyst Items 1.1 to 4.3.2

Dilan Savani, Health Technology Assessment Analyst Items 5.1 to 5.2.2

Suzie Panek, Business analyst, Resource Impact Present for all items

Korin Knight, Senior Medical Editor Items 1.1 to 4.3.2

Ella Fitzpatrick, Public Involvement Adviser Items 1.1 to 4.1.3

Sandra Robinson, Assistant Project Manager, Corporate Office Items 1.1 to 4.1.2

Rosalee Mason, Coordinator, Corporate Office Items 1.1 to 4.1.3

Liam Murray, Administrator, Committee Operations Present for all items

Marcia Miller, Administrator, Technology Appraisals Items 1.1 to 4.3.2

NICE staff (observers) present

Catrin Austin, Technical Analyst, Managed Access Items 4.1.3 to 4.3.2

Emily Eaton Turner, Commercial Liaison Items 4.1.3 to 4.3.2

Janine Wigmore, Public Involvement Adviser Items 1.1 to 4.1.3

External assessment group representatives present

Jonathan Shepherd, Principal Research Fellow, Southampton HTA Items 1.1 to 4.2.1

Keith Cooper, Senior Research Fellow, Southampton HTA Items 1.1 to 4.2.1

Clinical, Patient & NHS England experts present

John Bottoms, Patient expert, nominated by Prostate Cancer UK Items 1.1 to 4.1.3

Dr Stephen Allen, Patient expert, Acting Chairman, Tackle Prostate Cancer, nominated by Tackle Prostate Cancer Items 1.1 to 4.1.3

Professor Amit Bahl, Clinical expert, Consultant Oncologist (University Hospitals Bristol), nominated by Bayer Items 1.1 to 4.1.3

Dr Simon Hughes, Clinical expert, Consultant Clinical Oncologist (Guy’s and St. Thomas’), nominated by Bayer Items 1.1 to 4.1.3

Professor Peter Clark, NHS England Cancer Drugs Fund Clinical Lead, Items 1.1 to 4.3.2

Hugh Selsick, Clinical Expert, Consultant in Psychiatry and Sleep Medicine, Items 5.1 to 5.1.3

Dr Kirstie Anderson, Clinical Expert, Consultant Neurologist and Sleep Specialist, nominated by the British Sleep Society Items 5.1 to 5.1.3

Lisa Artis, Patient Expert, Deputy CEO of The Sleep Charity, nominated by The Sleep Charity Items 5.1 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Charles Crawley, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Iolo Doull, Nicky Welton and Mary Weatherstone.

### News and announcements

* 1. The Chair expressed his condolences for the passing of committee member Dr Mark Glover and acknowledged his years of service to the committee.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 8 February 2023.

1. **Appraisal of darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bayer Healthcare.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Prior to the meeting, Dr Warren Linley declared a direct financial interest as AstraZeneca is listed as a potential comparator company and he is currently engaged in a paid project with AstraZeneca in the area of mCRPC. It was agreed that his declaration would prevent Dr Linley from participating in discussions on this appraisal.
* Stephen Allen declared a financial interest as his nominating organisation, Tackle Prostate Cancer, have received income from the pharmaceutical industry. It was agreed that his declaration would not prevent Stephen from providing expert advice to the committee.
* Amit Bahl declared professional and financial interests as he has received meeting support and honoraria payments for educational meetings and advisory boards from Bayer, Astellas, Janssen, Novartis, EUSA, BMS, Pfizer and AAA. He also declared research grants to Institution from Sanofi, Janssen and Bayer. It was agreed that his declaration would not prevent Amit from providing expert advice to the committee.
* Dr Simon Hughes declared professional and direct financial interests: Guy’s Cancer Academy (for which he is the lead) received an unrestricted grant from Bayer PLC to develop an open access online e-learning course (CPD accredited) on the management of non-metastatic Castration Resistant Prostate Cancer (Bayer had no input regarding the content); He chaired an Advisory Board for Bayer PLC concerning the ARASENS trial and received an honorarium for this; He is a mentor on the Bayer “Future Leaders in Oncology” programme for which he receives an honorarium; He co-Chairs and co-organises the Annual PROSPECT meeting (a UK multidisciplinary prostate cancer meeting funded by Astellas) for which he receives an honorarium; He has also received honoraria from Astellas for delivering a webinar to Astellas Europe staff on managing the side effects of androgen deprivation and delivering a series of webinars on the management of bone health in patients on androgen deprivation; Guy’s Cancer Academy received an unrestricted grant from Astellas to develop a credit bearing course (at Kings College London) on prostate cancer for advanced non-medical practitioners; Guy’s Cancer Academy have just signed a contract with Janssen Brazil to run a 2-day preceptorship for visiting oncologists from Brazil to cover the whole spectrum of prostate cancer management (and are also exploring a similar model with their European team); He receives honoraria from AstraZeneca to advise on their PARP inhibitor research programme, and their clinician education programme around PARPi. It was agreed that his declaration would not prevent Dr Hughes from providing expert advice to the committee.
* Peter Wheatley-Price declared a financial interest as his employer, Takeda, manufacture Leuprorelin (Prostap), an LHRH agonist used in hormone sensitive stages of prostate cancer. It was agreed that his declaration would not prevent Peter from participating in discussions on this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Toby Smith, Nigel Westwood and Dr Rhiannon Owen.
  1. Part 2a – Closed session (members of the public, company representatives, clinical experts and patient experts were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (the external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10860>

1. **Appraisal of daridorexant for treating insomnia [ID3774]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Idorsia Pharmaceuticals.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Lisa Artis declared a financial interest as her organisation has some proposals submitted to Idorisa for funding, though none have come to fruition currently. It was agreed that her declaration would not prevent Lisa from providing expert advice to the committee.
* Hugh Selsick declared a financial interest as he has received some funding from Idorsia to sit on the risk advisory committee and for speaking at a preceptorship that they ran a few months ago. It was agreed that his declaration would not prevent Hugh from providing expert advice to the committee.
* Dr Kirstie Anderson declared professional interests as her employer has received educational support from a wide array of pharmaceutical companies around sleep products. She was involved in the clinical content of one of the online digital CBT companies (Sleepstation) between 2012 and 2017, but at no stage any financial interest or shareholdings. Kirstie also declared financial interests as she was paid to give a talk by Idorsia at an educational sleep meeting but not regarding this treatment. Prior to the meeting, she declared sponsorship of sleep conferences that she helped to arrange, honoraria and expert speaker’s fees from a number of pharmaceutical companies over the last 7 years (UCB, Bioprojet, ResMed, Jazz pharmaceuticals) but none for hypnotics. It was agreed that her declaration would not prevent Dr Anderson from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tony Wooton and Gabriel Rodgers.
  1. Part 2 – session (company representatives, clinical experts, patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/awaiting-development/gid-ta10888>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 5 April 2023 and will start promptly at 10:00am.